A novel missense mutation in the nuclear factor-κB essential modulator (NEMO) gene resulting in impaired activation of the NF-κB pathway and a unique clinical phenotype presenting as MRSA subdural empyema

J Clin Immunol. 2010 Nov;30(6):881-5. doi: 10.1007/s10875-010-9445-y. Epub 2010 Jul 23.

Abstract

Introduction: We describe a previously unreported 437 T→G missense mutation producing a V146G substitution in the first coiled-coil (CC1) domain of nuclear factor-κB essential modulator (NEMO) in a 9-month-old boy with ectodermal dysplasia with immunodeficiency who presented with methicillin-resistant Staphylococcus aureus subdural empyema. We performed in vitro experiments to determine if this novel mutation resulted in impaired NF-κB signaling.

Methods: IκBα phosphorylation experiments were performed using a Jurkat T cell line lacking endogenous NEMO expression that was transfected with vectors containing either the wild type or the patient's V146G mutation. The cells were stimulated with TNF-α to activate the NF-κB pathway. Phosphorylated IκBα was detected by immunoblotting with anti-phospho-IκBα antibodies. Peripheral blood mononuclear cells from the patient were stimulated with TNF-α or anti-CD3 and anti-CD28. Impaired IκBα degradation was detected using antibodies against the IκBα protein.

Results: While TNF-α stimulation resulted in IκBα phosphorylation in NEMO-deficient Jurkat cells reconstituted with wild-type NEMO, cell transfected with the V146G mutant exhibited a 75% reduction in phospho-IκBα. Peripheral blood mononuclear cells from the patient showed impaired degradation of IκBα after stimulation when compared with normal controls.

Conclusions: The patient's V146G mutation results in impaired NF-κB activation in vitro. The mutation extends the known N-terminal boundary within the CC1 domain that produces an ectodermal dysplasia phenotype, and defines an infectious susceptibility previously unappreciated in ectodermal dysplasia with immunodeficiency (methicillin-resistant S. aureus subdural empyema), broadening the clinical spectrum associated with the disease.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Bacterial*
  • Ectodermal Dysplasia
  • Empyema, Subdural / drug therapy
  • Empyema, Subdural / genetics*
  • Empyema, Subdural / metabolism
  • Empyema, Subdural / physiopathology
  • Humans
  • I-kappa B Kinase / genetics
  • I-kappa B Kinase / metabolism*
  • Infant
  • Jurkat Cells
  • Male
  • Methicillin / therapeutic use
  • Mutant Proteins / genetics
  • Mutation, Missense / genetics
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Signal Transduction
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / immunology*
  • Staphylococcus aureus / pathogenicity
  • Transcriptional Activation / genetics
  • Transgenes / genetics
  • Tumor Necrosis Factor-alpha / immunology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • IKBKG protein, human
  • Mutant Proteins
  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • I-kappa B Kinase
  • Methicillin